Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Epigenetic deregulation is a key driver of cancer progression, allowing tumor cells to evade immune surveillance.
• Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are critical enzymes regulating the epigenome through acetylation and deacetylation.
• Osteosarcoma exhibits significant genetic and epigenetic instability, contributing to poor therapeutic outcomes.

Purpose of the Study:

• To review the therapeutic potential of targeting the cancer epigenome in osteosarcoma.
• To focus on the application of histone deacetylase inhibitors (HDACi) for osteosarcoma treatment.
• To discuss the safety, tolerance, and combination strategies involving HDACi in osteosarcoma.

Main Methods:

• Literature review of epigenetic deregulation in cancer.
• Focus on histone deacetylase inhibitors (HDACi) as a therapeutic strategy.
• Analysis of safety, tolerance, and combination chemotherapy with HDACi.

Main Results:

• Epigenetic alterations are crucial in cancer development and progression.
• HDAC inhibitors represent a viable approach to restore epigenetic homeostasis in osteosarcoma.
• Challenges remain in the clinical development and application of HDACi for osteosarcoma.

Conclusions:

• Targeting epigenetic mechanisms, particularly with HDAC inhibitors, holds significant promise for osteosarcoma treatment.
• Further research is needed to optimize HDAC inhibitor therapies and overcome developmental challenges.
• Combination strategies may enhance the efficacy of HDAC inhibitors in osteosarcoma.